Author + information
- J. Brent Muhlestein,
- Jennifer Kammerer,
- Tami Bair,
- Kirk Knowlton,
- Viet T. Le,
- Jeffrey L. Anderson,
- Donald Lappe and
- Heidi Thomas May
Hyperkalemia (HK) is a serious medical condition that can lead to life-threatening cardiac arrhythmias and sudden cardiac death. HK can result from various acute and chronic conditions that affect potassium (K) homeostasis. However, HK incidence and subsequent clinical and economic outcomes within a large healthcare system have not been fully described.
Patients ≥18 years of age who received a non-spurious potassium (K) result were studied. Patients were stratified as not HK (non-HK, K ≤5.0 mmol/L) or HK (HK, at least one K >5.0 mmol/L).
A total of 1,208,815 met study criteria, with 161,849 (13.4%) having HK. Compared to non-HK patients, HK patients were older (60±18 vs. 43±18), more often male (51% vs. 41%), had more comorbidities, and incurred higher mean annual costs for emergency department (ED) ($552±7,574 vs. $207±1,930, p<0.0001) and inpatient stays ($10,956±93,026 vs. $1,477±21,423, p<0.0001). At 3 years, more HK patients experienced MACE (18.8% vs. 3.2%, p<0.0001), which persisted after adjustment (multivariable HR=1.67, p<0.0001). The Table shows differences among differing degrees of HK.
Within Intermountain Healthcare, HK is associated with a large clinical burden, involving more than 1 in 10 patients. It is associated with a marked increase in yearly ED and inpatient costs, and a two-thirds increase in 3 year MACE. Although risk worsens with the severity of HK, even mild HK is associated with a significant increase in medical costs and clinical risk.
Posters Hall_Hall A
Saturday, March 28, 2020, 12:30 p.m.-1:15 p.m.
Session Title: Prevention: Clinical 2
Abstract Category: 32. Prevention: Clinical
Presentation Number: 1161-122
- 2020 American College of Cardiology Foundation